Abstract
Background and Aims Crohn’s disease (CD) has a complex polygenic etiology with high heritability. We keep putting an effort to identify novel variants associated with susceptibility to CD through a genome-wide association study (GWAS) in large Korean populations.
Methods Genome-wide variant data from 902 Korean patients with CD and 72,179 controls were used to assess the genetic associations in a meta-analysis with previous Korean GWAS results from 1,621 patients with CD and 4,419 controls. Epistatic interactions between CD-risk variants of interest were tested using a multivariate logistic regression model with an interaction term.
Results We identified two novel genetic associations with the risk of CD near ZBTB38 and within the leukocyte immunoglobulin-like receptor (LILR) gene cluster (P<5×10−8), with highly consistent effect sizes between the two independent Korean cohorts. CD-risk variants in the LILR locus are known quantitative trait loci (QTL) for multiple LILR genes, of which LILRB2 directly interacts with various ligands including MHC class I molecules. The LILR lead variant exhibited a significant epistatic interaction with CD-associated regulatory variants for TAP2 involved in the antigen presentation of MHC class I molecules (P=4.11×10−4), showing higher CD-risk effects of the TAP2 variant in individuals carrying more risk alleles of the LILR lead variant (OR=0.941, P=0.686 in non-carriers; OR=1.45, P=2.51×10−4 in single-copy carriers; OR=2.38, P=2.76×10−6 in two-copy carriers).
Conclusions This study demonstrated that genetic variants at two novel susceptibility loci and the epistatic interaction between variants in LILR and TAP2 loci confer risk of CD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Research Foundation of Korea (NRF-2017R1A5A2014768 and NRF-2020R1A2B5B02002259).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Institutional Review Board of Kyung Hee University Hospital (KHUH 2018-03-006-018, KHUH 2021-04-082) and Kangbuk Samsung Medical Center (KBSMC 2016-07-029).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* K.K. and S.J.O. are co-first authors.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
